Distinct sets of genetic alterations in melanoma.

By J. Curtin, Jane Fridlyand, T. Kageshita, Hetal Patel, K. Busam, H. Kutzner, Kwang-Hyun Cho, S. Aiba, E. Bröcker, P. LeBoit and 2 more. New England Journal of Medicine, 2005

2,454 citations recorded by the source corpus.

Subfields: Cell Biology, Molecular Biology, Oncology

View Paper: https://www.semanticscholar.org/paper/c5c8c38409c67c1e589812ea0ab1d5736d0a7ed8

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Cell Biology

In Molecular Biology

In Oncology

Citations in the corpus

Colocalization of Inflammatory Response with B7-H1 Expression in Human Melanocytic Lesions Supports an Adaptive Resistance Mechanism of Immune Escape (2012, background): “Most patients had the acral lentiginous subtype of melanoma, which is associated with c-Kit mutations, rather than with BRAF mutations, which predominate in cohorts of European descent (51, 52).”
Melanoma genome sequencing reveals frequent PREX2 mutations (2012, neutral): “The elevated frequency of genomic rearrangements in acral melanomas has been reported previously 20 .”
Immune Checkpoint Targeting in Cancer Therapy: Towards Combination Strategies with Curative Potential (2015, background): “As an example of genomically targeted therapies, an inhibitor against BRAF was developed when it was discovered that 40%–60% of cutaneous melanomas carry mutations in BRAF, which induces constitutive activation of the MAPK pathway (Curtin et al., 2005; Davies et al., 2002).”
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation (2011, background): “Arthralgia Grade 2 60 (18) 1 (<1) Grade 3 11 (3) 2 (<1) Rash Grade 2 33 (10) 0 Grade 3 28 (8) 0 Fatigue Grade 2 38 (11) 33 (12) Grade 3 6 (2) 5 (2) Cutaneous squamous-cell carcinoma‡ Grade 3 40 (12) 1 (<1) Keratoacanthoma§ Grade 2 7 (2) 0 Grade 3 20 (6) 0 Nausea Grade 2 25 (7) 32 (11) Grade 3 4 (1) ”
Oncogenic BRAF regulates oxidative metabolism via PGC1α and MITF (2013, positive): “Activating mutations in the BRAF protein kinase are the most common genetic alterations in melanoma, found in 50% of tumors (Davies et al., 2002; Curtin et al., 2005).”
Genomic Classification of Cutaneous Melanoma (2015, result): “05), consistent with previous studies (Curtin et al., 2005), as well as MDM2 and TERT (p < 0.”
Germline mutations in BAP1 predispose to melanocytic tumors (2011, methodology): “Primers for GNAQ , GNA11 and BRAF were described previousl”
Combined vemurafenib and cobimetinib in BRAF-mutated melanoma. (2014, neutral): “Decreased ejection fraction 0 4 (2) 3 (1) 0 2 (1) 14 (6) 3 (1) 0”
A Landscape of Driver Mutations in Melanoma (2012, background): “Somatic copy-number aberration profiles identified expected melanoma alterations (Curtin et al., 2005; Lin et al., 2008), including gains ofMITF, TERT, and CCND1 and deletions ofCDKN2A and PTEN, among others (Figure S1A and Table S3).”
Melanoma biology and new targeted therapy (2007, background): “So far, melanoma diagnosis has been based on pathology, but Bastian and colleagues recently demonstrated that genome-wide alterations in DNA copy number together with analysis of individual somatic mutation can be used to distinguish between the different melanoma subtypes with 70p accurac”